Discontinued drugs in 2005: cardiovascular drugs

Bibliography

• GRUNDY SM: Metabolic syndrome: connecting and reconciling cardiovascular and diabetes worlds. J. Am. Coll. Cardiol. (2006) 47:1093-1100.
   PubMed Web of Science ®Google Scholar
• VASAN RS: Biomarkers of cardiovascular disease: molecular basis and practical considerations. Circulation (2006) 113:2335-2362.
   PubMed Web of Science ®Google Scholar
• TOBERT JA: Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors. Nat. Rev. Drug Discov. (2003) 2:517-526.
   PubMed Web of Science ®Google Scholar
• ARNAUD C, BRAUNERSREUTHER V, MACH F: Toward immunomodulatory and anti-inflammatory properties of statins. Trends Cardiovasc. Med. (2005) 15:202-206.
   PubMed Web of Science ®Google Scholar
• CHIANG JYL: Regulation of bile acid synthesis: pathways, nuclear receptors, and mechanisms. J. Hepatol. (2004) 40:539-551.
   PubMed Web of Science ®Google Scholar
• ALDRIDGE MA, ITO MK: Colesevelam hydrochloride: a novel bile acid-binding resin. Ann. Pharmacother. (2001) 35:898-907.
   PubMed Web of Science ®Google Scholar
• HIGAKI J, HARA S, TAKASU N et al.: Inhibition of ileal Na+ bile-acid cotransporter by S-8921 reduces serum-cholesterol and prevents atherosclerosis in rabbits. Arterioscler. Thromb. Vasc. Biol. (1998) 18:01304-01311.
   PubMed Web of Science ®Google Scholar
• ICHIHASHI T, IZAWA M, MIYATA K, MIZUI T, HIRANO K, TAKAGISHI Y: Mechanism of hypocholesterolemic action of S-8921 in rats: S-8921 inhibits ileal bile-acid absorption. J. Pharmacol. Exp. Ther. (1998) 284:43-50.
   PubMed Web of Science ®Google Scholar
• LI H, XU GR, SHANG Q et al.: Inhibition of ileal bile acid transport lowers plasma cholesterol levels by inactivating hepatic farnesoid X receptor and stimulating cholesterol 7 α-hydroxylase. Metab. Clin. Exp. (2004) 53:927-932.
   PubMed Web of Science ®Google Scholar
• BRUCKERT E, GIRAL P, TELLIER P: Perspectives in cholesterol-lowering therapy – the role of ezetimibe, a new selective inhibitor of intestinal cholesterol absorption. Circulation (2003) 107:3124-3128.
   PubMed Web of Science ®Google Scholar
• BURNETT DA: β-lactam cholesterol absorption inhibitors. Curr. Med. Chem. (2004) 11:1873-1887.
   PubMed Web of Science ®Google Scholar
• ALEGRET M, LLAVERIAS G, SILVESTRE JS: Acyl coenzyme A:cholesterol acyltransferase inhibitors as hypolipidemic and antiatherosclerotic drugs. Methods Findings Exp. Clin. Pharmacol. (2004) 26:563-586.
   PubMed Web of Science ®Google Scholar
• RUDEL LL, LEE RG, PARINI P: ACAT2 is a target for treatment of coronary heart disease associated with hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol. (2005) 25:1112-1118.
   PubMed Web of Science ®Google Scholar
• TARDIF JC, GREGOIRE J, L’ALLIER PL et al.: Effects of the acyl coenzyme A: cholesterol acyltransferase inhibitor avasimibe on human atherosclerotic lesions. Circulation (2004) 110:3372-3377.
   PubMed Web of Science ®Google Scholar
• KITAYAMA K, TANIMOTOT, KOGA T, TERASAKA N, FUJIOKA T, INABA T: Importance of acyl-coenzyme A:cholesterol acyltransferase 1/2 dual inhibition for anti-atherosclerotic potency of pactimibe. Eur. J. Pharmacol. (2006) 540(1-3):121-130.
   PubMed Web of Science ®Google Scholar
• KITAYAMA K, KOGA T, INABA T, FUJIOKA T: Multiple mechanisms of hypocholesterolemic action of pactimibe, a novel acyl-coenzyme A:cholesterol acyltransferase inhibitor. Eur. J. Pharmacol. (2006) 543(1-3):123-132.
   PubMed Web of Science ®Google Scholar
• KITAYAMA K, KOGA T, MAEDA N, INABA T, FUJIOKA T: Pactimibe stabilizes atherosclerotic plaque through macrophage acyl-CoA:cholesterol acyltransferase inhibition in WHHL rabbits. Eur. J. Pharmacol. (2006) 539:81-88.
   PubMed Web of Science ®Google Scholar
• TERASAKA N, MIYAZAKI A, KASANUKI N et al.: ACAT inhibitor pactimibe sulfate (CS-505) reduces and stabilizes atherosclerotic lesions by cholesterol-lowering and direct effects in apolipoprotein E-deficient mice. Atherosclerosis (2006) (In Press).
   PubMedGoogle Scholar
• NICHOLLS SJ, SIPAHI I, SCHOENHAGEN P, CROWE T, TUZCU EM, NISSEN SE: Application of intravascular ultrasound in anti-atherosclerotic drug development. Nat. Rev. Drug Discov. (2006) 5:485-492.
   PubMed Web of Science ®Google Scholar
• NISSEN SE, NICHOLLSSJ, SIPAHI I et al., FOR THE ASTEROID INVESTIGATORS: Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID Trial. JAMA (2006) 295:1556-1565.
   PubMed Web of Science ®Google Scholar
• STEPHEN J, NICHOLLS EMTISPSTCSKASEN: Relationship between atheroma regression and change in lumen size after infusion of apolipoproteinA-IMilano. J. Am. Coll. Cardiol. (2006) 47:992-997.
   PubMed Web of Science ®Google Scholar
• NISSEN SE, TUZCU EM,BREWER HB et al., THE ACAT INTRAVASCULAR ATHEROSCLEROSIS TREATMENTEVALUATION (ACTIVATE) INVESTIGATORS: Effect of ACAT inhibition on the progression of coronary atherosclerosis. N. Engl. J. Med. (2006) 354:1253-1263.
   PubMed Web of Science ®Google Scholar